Free Trial
→ Here’s How to Claim Your Stake in Elon’s Private Company, xAI (From Brownstone Research) (Ad) Buy PCRX Stock  Free PCRX Stock Alerts

Pacira BioSciences (PCRX) Financials

Pacira BioSciences logo
$26.45 -0.30 (-1.12%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$27.04 +0.59 (+2.23%)
As of 05/2/2025 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Pacira BioSciences

Annual Income Statements for Pacira BioSciences

This table shows Pacira BioSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -14 1.86 -38 -43 -0.47 -11 146 42 -15 9.34 -404
Consolidated Net Income / (Loss)		 -14 1.86 -38 -43 -0.47 -11 146 42 32 84 -199
Net Income / (Loss) Continuing Operations		 -14 1.86 -38 -43 -0.47 -11 146 42 -15 9.34 -404
Total Pre-Tax Income 		-14 2.12 -38 -42 -0.43 -11 20 56 27 123 -126
Total Operating Income		 -5.17 9.46 -32 -25 16 10 46 90 60 88 -73
Total Gross Profit		 120 177 166 199 250 314 312 401 1,134 1,165 1,232
Total Revenue		 198 249 276 287 337 421 430 542 1,334 1,350 1,402
Operating Revenue		 198 249 276 287 337 421 430 542 1,334 1,350 1,402
Total Cost of Revenue		 77 72 110 88 87 107 117 140 199 185 170
Operating Cost of Revenue		 77 72 110 88 87 107 117 140 199 185 170
Total Operating Expenses		 125 168 198 224 235 304 266 311 1,061 1,048 1,591
Selling, General & Admin Expense		 107 139 153 161 177 201 194 199 255 269 294
Research & Development Expense		 19 29 46 57 56 72 59 56 85 76 82
Amortization Expense		 - - - 0.00 0.00 5.70 7.87 14 115 115 115
Other Operating Expenses / (Income)		 - 0.00 0.00 - - - - 43 607 587 774
Impairment Charge		 - - - - - - 5.17 - 0.00 0.00 326
Total Other Income / (Expense), net		 -8.38 -7.34 -5.82 -18 -16 -21 -26 -34 -93 -69 28
Interest Expense		 8.28 7.78 7.06 22 22 24 34 32 40 54 1.53
Interest & Investment Income		 0.38 0.68 1.32 4.08 6.50 7.38 4.63 0.90 4.54 11 20
Other Income / (Expense), net		 -0.48 -0.24 -0.08 0.17 -0.89 -4.98 2.85 -2.67 -58 -26 9.89
Income Tax Expense		 0.17 0.26 0.11 0.14 0.05 0.27 -125 14 -5.21 39 73
Basic Earnings per Share		 ($0.39) $0.05 ($1.02) ($1.07) ($0.01) ($0.27) $3.41 $0.95 $0.35 $0.91 ($2.15)
Weighted Average Basic Shares Outstanding		 35.30M 36.54M 37.24M 39.81M 40.91M 41.51M 42.67M 44.26M 45.52M 46.22M 46.25M
Diluted Earnings per Share		 ($0.39) $0.04 ($1.02) ($1.07) ($0.01) ($0.27) $3.33 $0.92 $0.34 $0.89 ($2.15)
Weighted Average Diluted Shares Outstanding		 35.30M 41.30M 37.24M 39.81M 40.91M 41.51M 43.68M 45.63M 46.54M 51.98M 46.25M
Weighted Average Basic & Diluted Shares Outstanding		 35.30M 37.10M 37.24M 39.81M 40.91M 41.51M 43.86M 44.85M 45.95M 46.50M 46.28M

Quarterly Income Statements for Pacira BioSciences

This table shows Pacira BioSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -0.69 -41 -20 26 11 -7.74 8.98 19 -143 -289
Consolidated Net Income / (Loss)		 -0.69 5.81 -20 26 11 67 8.98 19 -143 -84
Net Income / (Loss) Continuing Operations		 -0.69 -41 -20 26 11 -7.74 8.98 19 -143 -289
Total Pre-Tax Income 		2.07 -4.77 -26 38 17 95 14 37 -139 -38
Total Operating Income		 21 -9.89 -3.09 40 18 33 13 28 -140 25
Total Gross Profit		 117 777 111 121 124 809 120 134 130 848
Total Revenue		 167 839 160 169 164 856 167 178 169 888
Operating Revenue		 167 839 160 169 164 856 167 178 169 888
Total Cost of Revenue		 51 62 49 48 40 48 47 44 39 40
Operating Cost of Revenue		 51 62 49 48 40 48 47 44 39 40
Total Operating Expenses		 95 773 114 81 106 745 106 106 269 1,110
Selling, General & Admin Expense		 61 64 71 65 68 66 72 68 74 80
Research & Development Expense		 19 18 17 19 21 19 18 20 19 24
Amortization Expense		 14 72 14 14 14 72 14 14 14 72
Total Other Income / (Expense), net		 -19 -55 -23 -2.02 -1.12 -42 0.43 8.34 0.67 19
Interest Expense		 9.86 11 27 3.87 3.46 20 3.32 -3.63 4.69 -2.84
Interest & Investment Income		 1.23 2.79 3.14 2.11 2.77 3.43 3.90 4.75 5.48 5.56
Other Income / (Expense), net		 -11 -47 -0.01 -0.27 -0.42 -25 -0.16 -0.04 -0.12 10
Income Tax Expense		 2.76 -11 -6.94 12 5.74 29 4.66 18 4.61 46
Basic Earnings per Share		 ($0.02) ($0.22) ($0.43) $0.56 $0.23 $0.55 $0.19 $0.41 ($3.11) $0.36
Weighted Average Basic Shares Outstanding		 45.83M 45.52M 45.95M 46.09M 46.42M 46.22M 46.50M 46.17M 46.13M 46.25M
Diluted Earnings per Share		 ($0.02) ($0.19) ($0.43) $0.51 $0.23 $0.58 $0.19 $0.39 ($3.11) $0.38
Weighted Average Diluted Shares Outstanding		 45.83M 46.54M 45.95M 52.05M 52.07M 51.98M 52.19M 50.54M 46.13M 46.25M
Weighted Average Basic & Diluted Shares Outstanding		 - 45.95M 45.99M 46.42M 46.44M 46.50M 46.55M 46.13M 46.17M 46.28M

Annual Cash Flow Statements for Pacira BioSciences

This table details how cash moves in and out of Pacira BioSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 25 19 -21 18 78 -54 22 486 -481 49 123
Net Cash From Operating Activities		 27 28 33 18 49 71 77 126 145 155 189
Net Cash From Continuing Operating Activities		 27 28 33 18 49 71 77 126 145 155 189
Net Income / (Loss) Continuing Operations		 -14 1.86 -38 -43 -0.47 -11 146 42 16 42 -100
Consolidated Net Income / (Loss)		 -14 1.86 -38 -43 -0.47 -11 146 42 16 42 -100
Depreciation Expense		 10 11 13 14 13 20 20 29 92 76 79
Amortization Expense		 4.63 4.58 4.57 12 13 15 18 26 7.21 3.75 3.22
Non-Cash Adjustments To Reconcile Net Income		 25 33 32 37 34 39 41 45 85 67 209
Changes in Operating Assets and Liabilities, net		 0.64 -23 22 -2.57 -11 7.90 -147 -16 -54 -34 -2.36
Net Cash From Investing Activities		 -120 -19 -62 -224 21 -128 -278 -21 -225 78 -83
Net Cash From Continuing Investing Activities		 -120 -19 -62 -224 21 -128 -278 -21 -225 78 -83
Purchase of Property, Plant & Equipment		 -23 -40 -25 -19 -15 -10 -38 -46 -30 -15 -11
Purchase of Investments		 -164 -189 -193 -503 -363 -320 -548 -629 -401 -144 -252
Sale and/or Maturity of Investments		 80 217 172 322 405 319 308 1,078 238 237 180
Other Investing Activities, net		 -13 -7.12 -16 -8.46 -6.84 0.00 0.00 -4.00 -32 0.00 0.00
Net Cash From Financing Activities		 119 11 7.26 224 8.95 3.67 222 381 -402 -183 17
Net Cash From Continuing Financing Activities		 119 11 7.26 224 8.95 3.67 222 381 -402 -183 17
Repayment of Debt		 0.00 -1.47 0.00 -129 0.00 -0.34 -189 0.00 -428 -336 -211
Repurchase of Common Equity		 - - - - - - - -4.55 -1.18 -1.16 -34
Issuance of Debt		 0.00 0.00 0.00 345 0.00 0.00 369 364 0.00 150 288
Issuance of Common Equity		 112 2.09 1.50 1.86 1.78 2.40 2.55 2.81 2.95 2.81 2.30
Other Financing Activities, net		 7.24 10 5.77 6.49 7.17 1.61 40 19 24 1.83 -27
Cash Interest Paid		 5.19 4.22 3.85 6.90 8.21 8.20 7.21 7.00 33 28 15
Cash Income Taxes Paid		 0.03 0.20 0.25 0.13 0.13 0.86 2.42 3.22 7.40 4.37 11

Quarterly Cash Flow Statements for Pacira BioSciences

This table details how cash moves in and out of Pacira BioSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -13 -5.29 -69 51 12 54 31 63 -1.09 31
Net Cash From Operating Activities		 43 42 19 43 44 48 49 53 54 33
Net Cash From Continuing Operating Activities		 43 42 19 43 44 48 49 53 54 33
Net Income / (Loss) Continuing Operations		 -0.69 -10 -20 26 11 25 8.98 19 -143 16
Consolidated Net Income / (Loss)		 -0.69 -10 -20 26 11 25 8.98 19 -143 16
Depreciation Expense		 20 30 20 19 18 18 18 19 20 21
Amortization Expense		 1.60 2.14 1.61 0.72 0.71 0.71 0.71 0.79 0.86 0.87
Non-Cash Adjustments To Reconcile Net Income		 23 39 29 11 15 12 13 5.04 176 15
Changes in Operating Assets and Liabilities, net		 -1.21 -19 -11 -13 -0.50 -8.62 7.77 9.66 -0.04 -20
Net Cash From Investing Activities		 -48 11 66 7.33 -4.34 8.37 -16 -15 -52 -0.37
Net Cash From Continuing Investing Activities		 -48 11 66 7.33 -4.34 8.37 -16 -15 -52 -0.37
Purchase of Property, Plant & Equipment		 -5.18 -5.49 -6.57 -3.40 -3.39 -1.80 -2.84 -1.59 -4.09 -2.12
Purchase of Investments		 -132 -68 -53 -23 -42 -26 -56 -50 -101 -45
Sale and/or Maturity of Investments		 90 85 126 34 41 36 43 36 53 47
Net Cash From Financing Activities		 -7.78 -59 -154 0.44 -28 -1.78 -2.82 25 -2.85 -1.96
Net Cash From Continuing Financing Activities		 -7.78 -59 -154 0.44 -28 -1.78 -2.82 25 -2.85 -1.96
Repayment of Debt		 -9.38 -59 -303 -2.81 -28 -2.81 -2.81 -202 -2.81 -2.81
Issuance of Common Equity		 -0.00 1.13 - - -0.00 1.14 - - - 0.93
Other Financing Activities, net		 1.60 0.91 0.33 1.58 0.03 -0.11 -0.00 -27 -0.03 -0.08
Cash Interest Paid		 8.93 9.68 18 3.17 4.13 2.70 3.97 3.02 3.20 5.23
Cash Income Taxes Paid		 0.11 3.18 0.20 0.59 1.28 2.29 -0.25 4.91 4.91 1.45

Annual Balance Sheets for Pacira BioSciences

This table presents Pacira BioSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 326 388 391 628 689 831 1,275 2,075 1,681 1,574 1,554
Total Current Assets		 214 253 243 391 478 409 652 866 498 510 745
Cash & Equivalents		 38 57 36 54 133 78 100 586 104 153 277
Short-Term Investments		 119 102 137 257 251 214 422 71 185 125 208
Accounts Receivable		 22 26 30 32 38 48 53 96 98 106 113
Inventories, net		 29 62 31 41 49 58 65 99 96 104 125
Prepaid Expenses		 4.46 6.12 9.28 6.69 7.95 11 12 15 15 22 22
Plant, Property, & Equipment, net		 61 90 101 107 109 105 137 188 184 174 167
Total Noncurrent Assets		 51 45 47 130 103 318 486 1,021 999 890 641
Long-Term Investments		 24 13 0.00 74 41 65 95 22 64 38 36
Goodwill		 24 31 47 55 62 100 100 145 163 163 0.00
Intangible Assets		 0.40 0.08 - - 0.00 104 97 624 541 483 426
Noncurrent Deferred & Refundable Income Taxes		 - - - - - 0.00 106 153 160 144 130
Other Noncurrent Operating Assets		 2.59 0.41 0.62 0.83 0.00 49 89 76 71 61 49
Total Liabilities & Shareholders' Equity		 326 388 391 628 689 831 1,275 2,075 1,681 1,574 1,554
Total Liabilities		 155 169 172 349 368 476 655 1,345 906 704 775
Total Current Liabilities		 140 150 45 56 61 108 253 521 148 97 310
Short-Term Debt		 103 104 0.00 0.32 0.34 0.00 150 375 34 8.64 202
Accounts Payable		 6.76 8.74 7.51 15 14 13 10 11 15 16 19
Accrued Expenses		 28 35 37 41 46 70 71 128 90 64 80
Other Current Liabilities		 0.28 - - - 0.00 23 22 7.89 9.12 8.80 8.89
Total Noncurrent Liabilities		 15 20 128 293 307 368 401 824 758 607 465
Long-Term Debt		 - 0.00 109 276 291 306 313 675 656 514 384
Other Noncurrent Operating Liabilities		 5.41 11 19 16 17 62 88 149 103 93 82
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 171 218 219 279 321 355 620 730 775 870 778
Total Preferred & Common Equity		 171 218 219 279 321 355 620 730 775 870 778
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 171 218 219 279 321 355 620 730 775 870 778
Common Stock		 481 527 565 669 710 754 873 942 924 977 1,009
Retained Earnings		 -310 -308 -346 -389 -388 -399 -254 -212 -149 -107 -206
Treasury Stock		 - - - - - - - - - 0.00 -25
Accumulated Other Comprehensive Income / (Loss)		 -0.08 -0.05 -0.03 -0.45 -0.28 0.32 0.32 0.17 -0.38 0.25 0.34

Quarterly Balance Sheets for Pacira BioSciences

This table presents Pacira BioSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 1,523 1,542 1,534 1,583 1,647 1,522
Total Current Assets		 376 429 447 543 632 690
Cash & Equivalents		 36 87 99 184 247 246
Short-Term Investments		 138 134 136 142 157 208
Accounts Receivable		 93 99 97 102 105 101
Inventories, net		 93 92 97 97 103 112
Prepaid Expenses		 16 17 19 19 20 24
Plant, Property, & Equipment, net		 182 180 176 172 169 167
Total Noncurrent Assets		 966 933 911 868 846 665
Long-Term Investments		 8.28 36 36 37 36 37
Goodwill		 163 163 163 163 163 0.00
Intangible Assets		 526 512 498 469 455 440
Noncurrent Deferred & Refundable Income Taxes		 168 156 152 141 135 134
Other Noncurrent Operating Assets		 100 66 63 59 56 54
Total Liabilities & Shareholders' Equity		 1,523 1,542 1,534 1,583 1,647 1,522
Total Liabilities		 755 734 703 691 768 772
Total Current Liabilities		 99 109 94 93 93 306
Short-Term Debt		 11 20 8.64 8.64 0.00 201
Accounts Payable		 17 24 17 8.98 19 19
Accrued Expenses		 62 56 60 67 65 76
Other Current Liabilities		 8.95 8.98 8.63 9.00 9.15 9.19
Total Noncurrent Liabilities		 657 625 609 598 675 466
Long-Term Debt		 543 532 516 512 589 386
Other Noncurrent Operating Liabilities		 114 93 93 86 86 80
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 768 808 832 892 879 750
Total Preferred & Common Equity		 768 808 832 892 879 750
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 768 808 832 892 879 750
Common Stock		 936 951 963 990 983 996
Retained Earnings		 -168 -143 -132 -98 -79 -222
Treasury Stock		 - - - - -25 -25
Accumulated Other Comprehensive Income / (Loss)		 -0.14 -0.17 -0.01 0.15 0.11 0.68

Annual Metrics and Ratios for Pacira BioSciences

This table displays calculated financial ratios and metrics derived from Pacira BioSciences' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 131.05% 25.97% 10.99% 3.71% 17.67% 24.83% 2.05% 26.04% 146.27% 1.22% 3.85%
EBITDA Growth		 120.58% 180.42% -157.84% 105.02% 5,484.60% -1.12% 115.54% 62.21% -28.92% 39.83% -86.84%
EBIT Growth		 89.53% 263.25% -448.26% 22.85% 160.67% -63.37% 793.93% 77.35% -97.69% 2,954.37% -203.19%
NOPAT Growth		 90.31% 328.95% -370.81% 22.13% 163.82% -34.15% 4,476.82% -80.07% 7.26% -16.95% -186.15%
Net Income Growth		 78.54% 113.53% -2,144.67% -12.28% 98.89% -2,238.85% 1,421.01% -71.15% -24.21% 163.72% -337.30%
EPS Growth		 79.79% 110.26% -2,650.00% -4.90% 99.07% -2,600.00% 1,333.33% -72.37% -63.04% 161.76% -341.57%
Operating Cash Flow Growth		 160.60% 5.48% 19.39% -46.84% 174.78% 44.30% 9.23% 63.20% 15.56% 6.45% 22.46%
Free Cash Flow Firm Growth		 47.81% -73.66% 45.03% -19.07% 80.33% -1,588.67% 260.50% -425.64% 110.82% 55.15% 89.20%
Invested Capital Growth		 37.97% 63.68% 3.41% 9.88% 10.32% 61.81% 52.92% 136.70% 0.93% -3.23% -21.58%
Revenue Q/Q Growth		 16.66% 3.12% 1.31% 2.20% 4.99% 6.94% 2.03% 5.50% 0.00% 102.79% 101.73%
EBITDA Q/Q Growth		 190.52% -24.91% -11.42% 105.67% 7.00% -17.14% 26.57% -4.35% 0.00% 3.05% 28.86%
EBIT Q/Q Growth		 76.08% -48.78% -5.38% 30.75% 31.61% -67.21% 59.09% -14.60% 0.00% 39.83% 1.91%
NOPAT Q/Q Growth		 77.45% -52.05% -5.43% 30.47% 31.34% -81.95% -64.95% -21.74% 0.00% 89.70% -13.04%
Net Income Q/Q Growth		 56.42% -81.73% -4.04% 16.74% 88.68% -610.71% 15.38% -31.88% 0.00% 1,101.63% -119.46%
EPS Q/Q Growth		 57.61% -85.71% -5.15% 18.94% 88.89% -640.00% 16.84% -34.75% 0.00% 641.67% -10.26%
Operating Cash Flow Q/Q Growth		 437.73% 8.82% 1.07% -2.30% 9.62% 7.11% 36.90% -15.72% 0.00% 3.72% -7.09%
Free Cash Flow Firm Q/Q Growth		 14.84% 2.28% 14.73% -19.30% 60.93% -51.46% -77.98% -1,397.82% -87.85% 109.06% -6.61%
Invested Capital Q/Q Growth		 13.07% 0.30% -3.40% 4.59% 0.05% 1.26% 0.06% 117.36% 0.00% -0.91% -0.35%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 60.82% 71.15% 60.16% 69.33% 74.25% 74.65% 72.69% 74.10% 85.06% 86.32% 87.84%
EBITDA Margin		 4.56% 10.15% -5.29% 0.26% 12.15% 9.63% 20.33% 26.17% 7.55% 10.43% 1.32%
Operating Margin		 -2.61% 3.80% -11.59% -8.70% 4.72% 2.49% 10.79% 16.61% 4.50% 6.49% -5.23%
EBIT Margin		 -2.86% 3.70% -11.62% -8.64% 4.46% 1.31% 11.45% 16.11% 0.15% 4.56% -4.53%
Profit (Net Income) Margin		 -6.94% 0.75% -13.73% -14.87% -0.14% -2.62% 33.87% 7.75% 2.39% 6.22% -14.20%
Tax Burden Percent		 101.28% 87.55% 100.28% 100.33% 110.82% 102.49% 724.39% 74.43% 119.60% 68.00% 157.77%
Interest Burden Percent		 239.83% 23.00% 117.87% 171.46% -2.83% -195.28% 40.83% 64.64% 1,320.95% 200.60% 198.82%
Effective Tax Rate		 0.00% 12.45% 0.00% 0.00% 0.00% 0.00% -624.39% 25.57% -19.60% 32.00% 0.00%
Return on Invested Capital (ROIC)		 -4.57% 6.85% -14.69% -10.72% 6.22% 2.98% 87.27% 8.55% 6.49% 5.45% -5.35%
ROIC Less NNEP Spread (ROIC-NNEP)		 32.61% 15.54% 8.80% 18.37% 15.80% 22.94% 272.73% -14.51% -4.81% 14.42% -114.62%
Return on Net Nonoperating Assets (RNNOA)		 -8.34% -5.90% -2.66% -6.37% -6.37% -6.24% -57.41% -2.33% -2.26% 4.75% -18.81%
Return on Equity (ROE)		 -12.92% 0.95% -17.35% -17.10% -0.16% -3.26% 29.86% 6.22% 4.23% 10.20% -24.16%
Cash Return on Invested Capital (CROIC)		 -36.49% -41.45% -18.04% -20.14% -3.60% -44.23% 45.42% -72.66% 5.57% 8.74% 18.84%
Operating Return on Assets (OROA)		 -2.28% 2.58% -8.24% -4.86% 2.28% 0.72% 4.67% 5.21% 0.11% 3.78% -4.06%
Return on Assets (ROA)		 -5.53% 0.52% -9.74% -8.36% -0.07% -1.45% 13.82% 2.51% 1.69% 5.15% -12.73%
Return on Common Equity (ROCE)		 -12.92% 0.95% -17.35% -17.10% -0.16% -3.26% 29.86% 6.22% 4.23% 10.20% -24.16%
Return on Equity Simple (ROE_SIMPLE)		 -8.01% 0.85% -17.33% -15.25% -0.15% -3.10% 23.48% 5.75% 4.11% 9.64% -25.58%
Net Operating Profit after Tax (NOPAT)		 -3.62 8.28 -22 -17 11 7.34 336 67 72 60 -51
NOPAT Margin		 -1.83% 3.32% -8.11% -6.09% 3.30% 1.74% 78.15% 12.36% 5.38% 4.42% -3.66%
Net Nonoperating Expense Percent (NNEP)		 -37.19% -8.68% -23.49% -29.10% -9.59% -19.96% -185.46% 23.06% 11.30% -8.97% 109.27%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 4.90% 4.28% -3.77%
Cost of Revenue to Revenue		 39.18% 28.85% 39.84% 30.67% 25.75% 25.35% 27.31% 25.90% 14.94% 13.68% 12.16%
SG&A Expenses to Revenue		 53.96% 55.84% 55.22% 56.34% 52.56% 47.69% 45.04% 36.81% 19.08% 19.96% 20.98%
R&D to Revenue		 9.48% 11.51% 16.53% 19.99% 16.51% 17.13% 13.83% 10.26% 6.36% 5.65% 5.82%
Operating Expenses to Revenue		 63.44% 67.35% 71.75% 78.03% 69.53% 72.17% 61.90% 57.49% 79.53% 77.60% 113.49%
Earnings before Interest and Taxes (EBIT)		 -5.65 9.22 -32 -25 15 5.50 49 87 2.01 62 -63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 9.01 25 -15 0.73 41 41 87 142 101 141 19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 18.68 12.92 5.52 6.63 5.51 5.33 4.20 3.67 2.28 1.80 1.12
Price to Tangible Book Value (P/TBV)		 21.75 15.06 7.01 8.26 6.82 12.52 6.14 0.00 24.84 7.01 2.47
Price to Revenue (P/Rev)		 16.17 11.34 4.37 6.46 5.24 4.49 6.05 4.95 1.33 1.16 0.62
Price to Earnings (P/E)		 0.00 1,520.80 0.00 0.00 0.00 0.00 17.86 63.85 0.00 167.68 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.07% 0.00% 0.00% 0.00% 0.00% 5.60% 1.57% 0.00% 0.60% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 34.01 18.36 7.38 10.23 8.70 6.05 5.26 2.77 1.89 1.65 1.11
Enterprise Value to Revenue (EV/Rev)		 15.77 11.06 4.14 6.08 4.85 4.37 5.69 5.63 1.58 1.31 0.67
Enterprise Value to EBITDA (EV/EBITDA)		 345.82 108.96 0.00 2,374.63 39.90 45.39 27.99 21.53 20.91 12.58 50.46
Enterprise Value to EBIT (EV/EBIT)		 0.00 298.75 0.00 0.00 108.84 334.25 49.70 34.97 1,045.54 28.81 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 332.73 0.00 0.00 146.81 250.78 7.28 45.59 29.33 29.73 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 117.35 98.29 34.20 98.00 33.47 26.09 31.74 24.27 14.49 11.46 4.94
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 13.99 0.00 34.20 18.55 5.17
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.60 0.48 0.50 0.99 0.91 0.86 0.75 1.44 0.89 0.60 0.75
Long-Term Debt to Equity		 0.00 0.00 0.50 0.99 0.90 0.86 0.51 0.92 0.85 0.59 0.49
Financial Leverage		 -0.26 -0.38 -0.30 -0.35 -0.40 -0.27 -0.21 0.16 0.47 0.33 0.16
Leverage Ratio		 2.33 1.83 1.78 2.05 2.19 2.25 2.16 2.48 2.50 1.98 1.90
Compound Leverage Factor		 5.60 0.42 2.10 3.51 -0.06 -4.39 0.88 1.60 32.96 3.97 3.77
Debt to Total Capital		 37.59% 32.27% 33.18% 49.73% 47.53% 46.30% 42.75% 58.96% 47.08% 37.52% 42.92%
Short-Term Debt to Total Capital		 37.59% 32.27% 0.00% 0.06% 0.06% 0.00% 13.83% 21.05% 2.30% 0.62% 14.80%
Long-Term Debt to Total Capital		 0.00% 0.00% 33.18% 49.67% 47.47% 46.30% 28.92% 37.90% 44.78% 36.90% 28.13%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 62.41% 67.73% 66.82% 50.27% 52.47% 53.70% 57.25% 41.04% 52.92% 62.48% 57.08%
Debt to EBITDA		 11.44 4.12 -7.44 376.70 7.10 7.55 5.30 7.40 6.85 3.71 31.59
Net Debt to EBITDA		 -8.82 -2.71 4.37 -148.56 -3.25 -1.25 -1.77 2.62 3.34 1.46 3.51
Long-Term Debt to EBITDA		 0.00 0.00 -7.44 376.26 7.09 7.55 3.58 4.76 6.51 3.65 20.70
Debt to NOPAT		 -28.52 12.57 -4.85 -15.84 26.11 41.72 1.38 15.68 9.60 8.76 -11.40
Net Debt to NOPAT		 21.99 -8.26 2.85 6.25 -11.96 -6.91 -0.46 5.54 4.69 3.45 -1.27
Long-Term Debt to NOPAT		 0.00 0.00 -4.85 -15.82 26.08 41.72 0.93 10.08 9.14 8.62 -7.47
Altman Z-Score		 11.87 9.93 4.01 3.28 3.38 2.67 2.94 1.65 2.10 2.54 1.59
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.53 1.69 5.42 6.96 7.88 3.79 2.57 1.66 3.37 5.24 2.40
Quick Ratio		 1.28 1.23 4.52 6.10 6.95 3.15 2.27 1.44 2.62 3.94 1.93
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -50 -28 -33 -6.45 -109 175 -569 62 96 181
Operating Cash Flow to CapEx		 115.58% 69.54% 135.39% 92.31% 336.71% 694.16% 203.78% 274.10% 483.02% 1,020.04% 1,780.64%
Free Cash Flow to Firm to Interest Expense		 -3.48 -6.44 -3.90 -1.51 -0.29 -4.61 5.18 -17.92 1.54 1.76 117.91
Operating Cash Flow to Interest Expense		 3.21 3.60 4.74 0.82 2.23 2.98 2.28 3.96 3.63 2.86 123.54
Operating Cash Flow Less CapEx to Interest Expense		 0.43 -1.58 1.24 -0.07 1.57 2.55 1.16 2.52 2.88 2.58 116.60
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.80 0.70 0.71 0.56 0.51 0.55 0.41 0.32 0.71 0.83 0.90
Accounts Receivable Turnover		 10.70 10.33 9.91 9.31 9.68 9.85 8.54 7.25 13.70 13.24 12.81
Inventory Turnover		 3.46 1.58 2.37 2.42 1.93 2.00 1.91 1.72 2.05 1.84 1.48
Fixed Asset Turnover		 3.63 3.30 2.89 2.76 3.13 3.95 3.56 3.33 7.17 7.55 8.22
Accounts Payable Turnover		 15.76 9.27 13.55 7.93 5.98 7.86 10.10 13.37 15.47 11.95 9.79
Days Sales Outstanding (DSO)		 34.12 35.34 36.84 39.22 37.69 37.07 42.72 50.34 26.65 27.57 28.49
Days Inventory Outstanding (DIO)		 105.63 230.95 154.02 150.89 189.09 182.76 191.24 212.36 178.21 198.06 245.90
Days Payable Outstanding (DPO)		 23.16 39.37 26.93 46.02 61.00 46.46 36.13 27.29 23.59 30.55 37.30
Cash Conversion Cycle (CCC)		 116.59 226.92 163.93 144.09 165.78 173.37 197.83 235.40 181.27 195.08 237.09
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 92 150 155 170 188 304 465 1,101 1,111 1,076 843
Invested Capital Turnover		 2.50 2.06 1.81 1.76 1.88 1.71 1.12 0.69 1.21 1.23 1.46
Increase / (Decrease) in Invested Capital		 25 58 5.11 15 18 116 161 636 10 -36 -232
Enterprise Value (EV)		 3,117 2,754 1,144 1,743 1,636 1,840 2,445 3,051 2,106 1,772 935
Market Capitalization		 3,197 2,823 1,208 1,852 1,769 1,890 2,600 2,680 1,769 1,567 870
Book Value per Share		 $4.75 $5.94 $5.85 $6.89 $7.81 $8.51 $14.26 $16.40 $17.03 $18.74 $16.86
Tangible Book Value per Share		 $4.08 $5.10 $4.61 $5.53 $6.30 $3.62 $9.75 ($0.87) $1.56 $4.82 $7.63
Total Capital		 274 322 328 556 612 661 1,082 1,780 1,464 1,393 1,364
Total Debt		 103 104 109 276 291 306 463 1,049 689 522 585
Total Long-Term Debt		 0.00 0.00 109 276 291 306 313 675 656 514 384
Net Debt		 -79 -68 -64 -109 -133 -51 -154 371 336 205 65
Capital Expenditures (CapEx)		 23 40 25 19 15 10 38 46 30 15 11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 19 48 26 24 34 8.93 26 63 96 143 152
Debt-free Net Working Capital (DFNWC)		 177 207 198 335 418 301 548 720 384 421 637
Net Working Capital (NWC)		 74 103 198 335 417 301 398 345 351 413 435
Net Nonoperating Expense (NNE)		 10 6.42 16 25 12 18 190 25 40 -24 148
Net Nonoperating Obligations (NNO)		 -79 -68 -64 -109 -133 -51 -154 371 336 205 65
Total Depreciation and Amortization (D&A)		 15 16 17 26 26 35 38 54 99 79 82
Debt-free, Cash-free Net Working Capital to Revenue		 9.70% 19.22% 9.28% 8.33% 10.14% 2.12% 6.12% 11.67% 7.17% 10.57% 10.87%
Debt-free Net Working Capital to Revenue		 89.72% 83.07% 71.73% 116.95% 123.83% 71.46% 127.53% 132.89% 28.81% 31.20% 45.44%
Net Working Capital to Revenue		 37.56% 41.28% 71.73% 116.84% 123.73% 71.46% 92.70% 63.70% 26.29% 30.56% 31.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.39) $0.05 ($1.02) ($1.07) ($0.01) ($0.27) $3.41 $0.95 $0.35 $0.91 ($2.15)
Adjusted Weighted Average Basic Shares Outstanding		 36.24M 36.54M 37.24M 39.81M 41.23M 42.03M 42.67M 44.26M 45.52M 46.22M 46.25M
Adjusted Diluted Earnings per Share		 ($0.39) $0.04 ($1.02) ($1.07) ($0.01) ($0.27) $3.33 $0.92 $0.34 $0.89 ($2.15)
Adjusted Weighted Average Diluted Shares Outstanding		 36.24M 41.30M 37.24M 39.81M 41.23M 42.03M 43.68M 45.63M 46.54M 51.98M 46.25M
Adjusted Basic & Diluted Earnings per Share		 ($0.39) $0.00 $0.00 $0.00 ($0.01) ($0.27) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.30M 37.05M 37.53M 40.71M 40.91M 41.51M 43.86M 44.85M 45.95M 46.50M 46.28M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.62 8.28 -22 -14 12 25 36 67 42 60 177
Normalized NOPAT Margin		 -1.83% 3.32% -8.11% -4.90% 3.63% 5.94% 8.39% 12.36% 3.15% 4.42% 12.64%
Pre Tax Income Margin		 -6.85% 0.85% -13.69% -14.82% -0.13% -2.55% 4.68% 10.42% 1.99% 9.14% -9.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -0.68 1.19 -4.55 -1.14 0.68 0.23 1.46 2.75 0.05 1.14 -41.41
NOPAT to Interest Expense		 -0.44 1.06 -3.17 -0.80 0.51 0.31 9.95 2.11 1.80 1.10 -33.50
EBIT Less CapEx to Interest Expense		 -3.46 -4.00 -8.05 -2.02 0.02 -0.20 0.34 1.30 -0.70 0.86 -48.35
NOPAT Less CapEx to Interest Expense		 -3.21 -4.12 -6.67 -1.69 -0.15 -0.12 8.83 0.66 1.04 0.82 -40.44
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.83% 3.69% 1.39% -17.25%

Quarterly Metrics and Ratios for Pacira BioSciences

This table displays calculated financial ratios and metrics derived from Pacira BioSciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 1.49% 0.03% -2.11% 2.08% 4.23% 5.05% 2.83% 3.74%
EBITDA Growth		 -25.53% 0.00% -53.78% 11.97% 12.16% 212.17% 77.68% -19.42% -425.28% 111.97%
EBIT Growth		 -65.94% 0.00% -117.96% 29.49% 61.81% 113.64% 520.93% -28.80% -907.27% 352.93%
NOPAT Growth		 -131.13% 0.00% -113.29% -3.80% 262.55% 435.42% 501.96% -46.28% -942.66% -25.55%
Net Income Growth		 0.00% 0.00% -386.12% 29.62% 1,666.81% 1,050.77% 145.96% -26.69% -1,421.29% -224.98%
EPS Growth		 0.00% 0.00% -386.67% 27.50% 1,250.00% 405.26% 144.19% -23.53% -1,452.17% -34.48%
Operating Cash Flow Growth		 -29.25% 0.00% -37.85% 45.94% 4.18% 13.20% 156.70% 22.38% 21.34% -30.37%
Free Cash Flow Firm Growth		 2,761.92% 97.31% 100.53% 113.63% -314.97% 445.23% 2,839.88% 7.20% 113.16% 321.65%
Invested Capital Growth		 -100.00% 0.93% -0.48% -4.90% 0.00% -3.23% -7.85% -6.84% -22.02% -21.58%
Revenue Q/Q Growth		 -1.15% 400.86% -6.75% 5.69% -3.27% 422.32% -7.79% 6.53% -5.31% 426.90%
EBITDA Q/Q Growth		 -38.74% -173.83% -20.34% 227.84% -38.63% -26.17% -39.13% 48.68% -347.72% 148.11%
EBIT Q/Q Growth		 -65.05% -628.80% 68.40% 1,377.27% -56.32% -55.44% -61.25% 116.05% -595.19% 125.00%
NOPAT Q/Q Growth		 -125.28% 2.88% 68.76% 1,354.33% -57.29% 100.41% -64.45% 67.62% -769.95% 117.71%
Net Income Q/Q Growth		 -103.49% 937.95% -93.39% 231.87% -57.85% 515.44% -63.90% 110.34% -859.64% 41.78%
EPS Q/Q Growth		 -105.00% -850.00% -126.32% 218.60% -54.90% 152.17% -67.24% 105.26% -897.44% 112.22%
Operating Cash Flow Q/Q Growth		 43.11% -1.45% -54.50% 127.41% 2.16% 7.08% 3.19% 8.42% 1.28% -38.55%
Free Cash Flow Firm Q/Q Growth		 181.10% -103.43% 119.49% 2,414.11% -1,379.05% 105.51% 62.57% -8.33% 57.03% 76.48%
Invested Capital Q/Q Growth		 -100.00% 0.00% 2.53% -3.18% -1.62% -0.91% -2.37% -2.11% -17.65% -0.35%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 69.74% 92.62% 69.43% 71.55% 75.75% 94.43% 71.63% 75.14% 76.95% 95.51%
EBITDA Margin		 19.40% -2.86% 11.30% 35.04% 22.23% 3.14% 19.26% 26.88% -70.32% 6.42%
Operating Margin		 12.71% -1.18% -1.93% 23.53% 10.81% 3.87% 7.91% 15.86% -82.77% 2.78%
EBIT Margin		 6.38% -6.74% -1.93% 23.37% 10.55% 0.90% 7.81% 15.84% -82.84% 3.93%
Profit (Net Income) Margin		 -0.41% 0.69% -12.18% 15.20% 6.62% 7.80% 5.37% 10.61% -85.11% -9.40%
Tax Burden Percent		 -33.49% -121.84% 73.79% 68.06% 65.41% 70.03% 65.83% 51.62% 103.32% 222.24%
Interest Burden Percent		 19.35% 8.43% 853.72% 95.57% 95.97% 1,237.79% 104.50% 129.73% 99.43% -107.63%
Effective Tax Rate		 133.49% 0.00% 0.00% 31.94% 34.59% 29.97% 34.17% 48.38% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -1.00% -0.79% 9.47% 8.67% 3.35% 3.24% 5.31% -41.69% 2.84%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 2.61% -5.10% 9.08% 8.10% 19.44% 3.35% 7.25% -67.81% -71.71%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 1.22% -2.78% 4.05% 2.47% 6.40% 1.07% 1.91% -15.04% -11.76%
Return on Equity (ROE)		 0.00% 0.23% -3.57% 13.52% 11.14% 9.75% 4.31% 7.21% -56.72% -8.92%
Cash Return on Invested Capital (CROIC)		 200.00% 5.57% 2.90% 8.00% -194.21% 8.74% 14.75% 12.56% 20.04% 18.84%
Operating Return on Assets (OROA)		 0.00% -4.79% -0.76% 9.55% 9.16% 0.75% 3.43% 6.86% -37.68% 3.52%
Return on Assets (ROA)		 0.00% 0.49% -4.78% 6.21% 5.75% 6.47% 2.36% 4.59% -38.71% -8.43%
Return on Common Equity (ROCE)		 0.00% 0.23% -3.57% 13.52% 11.14% 9.75% 4.31% 7.21% -56.72% -8.92%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -1.36% -0.57% 0.84% 0.00% 7.90% 7.23% -12.10% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.13 -6.93 -2.16 27 12 23 8.70 15 -98 17
NOPAT Margin		 -4.26% -0.83% -1.35% 16.01% 7.07% 2.71% 5.20% 8.19% -57.94% 1.95%
Net Nonoperating Expense Percent (NNEP)		 6.07% -3.60% 4.31% 0.39% 0.58% -16.09% -0.11% -1.94% 26.12% 74.55%
Return On Investment Capital (ROIC_SIMPLE)		 - -0.47% - - - 1.67% - - - 1.27%
Cost of Revenue to Revenue		 30.26% 7.38% 30.57% 28.45% 24.25% 5.57% 28.37% 24.86% 23.05% 4.49%
SG&A Expenses to Revenue		 36.59% 7.63% 44.18% 38.27% 41.45% 7.69% 43.10% 38.27% 44.10% 8.96%
R&D to Revenue		 11.59% 2.09% 10.69% 11.11% 12.71% 2.27% 10.91% 11.42% 11.33% 2.69%
Operating Expenses to Revenue		 57.03% 92.17% 71.36% 48.02% 64.94% 87.05% 63.72% 59.27% 159.71% 124.95%
Earnings before Interest and Taxes (EBIT)		 11 -57 -3.10 40 17 7.71 13 28 -140 35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 32 -24 18 59 36 27 32 48 -119 57
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.28 2.44 2.28 1.71 1.80 1.52 1.51 0.93 1.12
Price to Tangible Book Value (P/TBV)		 0.00 24.84 23.87 13.87 8.34 7.01 5.23 5.09 2.24 2.47
Price to Revenue (P/Rev)		 0.00 1.33 2.80 2.75 2.14 1.16 1.99 1.93 1.00 0.62
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 203.93 167.68 19.28 20.94 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.49% 0.60% 5.19% 4.78% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.89 1.97 1.94 1.55 1.65 1.44 1.44 0.93 1.11
Enterprise Value to Revenue (EV/Rev)		 0.00 1.58 3.36 3.19 2.52 1.31 2.22 2.14 1.14 0.67
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 20.91 17.78 16.11 12.28 12.58 8.38 8.74 55.02 50.46
Enterprise Value to EBIT (EV/EBIT)		 0.00 1,045.54 79.21 57.19 38.14 28.81 14.63 16.05 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 29.33 81.18 63.39 53.39 29.73 21.07 25.35 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 14.49 16.81 14.51 11.25 11.46 8.21 7.62 3.88 4.94
Enterprise Value to Free Cash Flow (EV/FCFF)		 4.81 34.20 67.71 23.61 0.00 18.55 9.39 11.06 4.09 5.17
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.89 0.72 0.68 0.63 0.60 0.58 0.67 0.78 0.75
Long-Term Debt to Equity		 0.00 0.85 0.71 0.66 0.62 0.59 0.57 0.67 0.51 0.49
Financial Leverage		 -0.30 0.47 0.55 0.45 0.31 0.33 0.32 0.26 0.22 0.16
Leverage Ratio		 1.89 2.50 2.31 2.09 1.85 1.98 1.87 1.89 1.93 1.90
Compound Leverage Factor		 0.37 0.21 19.73 2.00 1.77 24.49 1.96 2.45 1.92 -2.04
Debt to Total Capital		 0.00% 47.08% 41.89% 40.58% 38.68% 37.52% 36.84% 40.13% 43.93% 42.92%
Short-Term Debt to Total Capital		 0.00% 2.30% 0.82% 1.43% 0.64% 0.62% 0.61% 0.00% 15.07% 14.80%
Long-Term Debt to Total Capital		 0.00% 44.78% 41.07% 39.14% 38.05% 36.90% 36.23% 40.13% 28.86% 28.13%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 52.92% 58.11% 59.42% 61.32% 62.48% 63.16% 59.87% 56.07% 57.08%
Debt to EBITDA		 0.00 6.85 4.38 4.16 3.84 3.71 2.88 3.48 40.85 31.59
Net Debt to EBITDA		 0.00 3.34 2.94 2.23 1.86 1.46 0.87 0.88 6.73 3.51
Long-Term Debt to EBITDA		 0.00 6.51 4.30 4.01 3.78 3.65 2.83 3.48 26.84 20.70
Debt to NOPAT		 0.00 9.60 20.01 16.36 16.69 8.76 7.23 10.09 -12.93 -11.40
Net Debt to NOPAT		 0.00 4.69 13.42 8.76 8.08 3.45 2.19 2.54 -2.13 -1.27
Long-Term Debt to NOPAT		 0.00 9.14 19.62 15.78 16.42 8.62 7.11 10.09 -8.49 -7.47
Altman Z-Score		 0.00 1.98 1.99 2.14 1.84 2.43 1.89 1.84 0.79 1.80
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 3.37 3.81 3.94 4.78 5.24 5.81 6.82 2.25 2.40
Quick Ratio		 0.00 2.62 2.71 2.94 3.55 3.94 4.58 5.49 1.81 1.93
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 500 -17 3.34 84 -1,074 59 98 90 141 249
Operating Cash Flow to CapEx		 823.28% 765.42% 291.36% 1,277.88% 1,309.31% 2,646.50% 1,731.35% 3,348.18% 1,317.69% 1,564.31%
Free Cash Flow to Firm to Interest Expense		 50.68 -1.55 0.13 21.72 -309.99 2.91 29.61 0.00 30.14 0.00
Operating Cash Flow to Interest Expense		 4.33 3.81 0.72 11.25 12.83 2.34 14.81 0.00 11.50 0.00
Operating Cash Flow Less CapEx to Interest Expense		 3.80 3.31 0.47 10.37 11.85 2.25 13.95 0.00 10.63 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.71 0.39 0.41 0.87 0.83 0.44 0.43 0.45 0.90
Accounts Receivable Turnover		 0.00 13.70 7.22 7.04 0.00 13.24 7.00 6.77 7.03 12.81
Inventory Turnover		 0.00 2.05 2.16 2.18 0.00 1.84 1.93 1.83 1.71 1.48
Fixed Asset Turnover		 0.00 7.17 3.60 3.60 0.00 7.55 3.86 3.95 4.06 8.22
Accounts Payable Turnover		 0.00 15.47 13.22 10.99 0.00 11.95 13.95 8.34 9.94 9.79
Days Sales Outstanding (DSO)		 0.00 26.65 50.54 51.86 0.00 27.57 52.16 53.89 51.89 28.49
Days Inventory Outstanding (DIO)		 0.00 178.21 169.08 167.62 0.00 198.06 189.17 199.26 213.37 245.90
Days Payable Outstanding (DPO)		 0.00 23.59 27.61 33.22 0.00 30.55 26.16 43.75 36.74 37.30
Cash Conversion Cycle (CCC)		 0.00 181.27 192.02 186.27 0.00 195.08 215.17 209.41 228.53 237.09
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 1,111 1,140 1,103 1,085 1,076 1,050 1,028 846 843
Invested Capital Turnover		 0.00 1.21 0.59 0.59 1.23 1.23 0.62 0.65 0.72 1.46
Increase / (Decrease) in Invested Capital		 -507 10 -5.50 -57 1,085 -36 -89 -75 -239 -232
Enterprise Value (EV)		 2,437 2,106 2,247 2,138 1,678 1,772 1,517 1,480 791 935
Market Capitalization		 2,437 1,769 1,875 1,843 1,424 1,567 1,359 1,332 694 870
Book Value per Share		 $0.00 $17.03 $16.71 $17.57 $17.91 $18.74 $19.19 $18.89 $16.25 $16.86
Tangible Book Value per Share		 $0.00 $1.56 $1.71 $2.89 $3.68 $4.82 $5.59 $5.62 $6.71 $7.63
Total Capital		 0.00 1,464 1,322 1,360 1,356 1,393 1,412 1,469 1,337 1,364
Total Debt		 0.00 689 554 552 525 522 520 589 587 585
Total Long-Term Debt		 0.00 656 543 532 516 514 512 589 386 384
Net Debt		 0.00 336 371 295 254 205 158 149 97 65
Capital Expenditures (CapEx)		 5.18 5.49 6.57 3.40 3.39 1.80 2.84 1.59 4.09 2.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 96 114 119 127 143 132 135 131 152
Debt-free Net Working Capital (DFNWC)		 0.00 384 288 340 362 421 458 540 585 637
Net Working Capital (NWC)		 0.00 351 277 320 354 413 450 540 384 435
Net Nonoperating Expense (NNE)		 -6.44 -13 17 1.38 0.73 -44 -0.28 -4.31 46 101
Net Nonoperating Obligations (NNO)		 0.00 336 371 295 254 205 158 149 97 65
Total Depreciation and Amortization (D&A)		 22 33 21 20 19 19 19 20 21 22
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 7.17% 17.08% 17.80% 19.09% 10.57% 19.42% 19.60% 18.88% 10.87%
Debt-free Net Working Capital to Revenue		 0.00% 28.81% 43.08% 50.79% 54.42% 31.20% 67.23% 78.16% 84.18% 45.44%
Net Working Capital to Revenue		 0.00% 26.29% 41.46% 47.88% 53.12% 30.56% 65.96% 78.16% 55.19% 31.04%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.22) ($0.43) $0.56 $0.23 $0.55 $0.19 $0.41 ($3.11) $0.36
Adjusted Weighted Average Basic Shares Outstanding		 0.00 45.52M 45.95M 46.09M 46.42M 46.22M 46.50M 46.17M 46.13M 46.25M
Adjusted Diluted Earnings per Share		 $0.00 ($0.19) ($0.43) $0.51 $0.23 $0.58 $0.19 $0.39 ($3.11) $0.38
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 46.54M 45.95M 52.05M 52.07M 51.98M 52.19M 50.54M 46.13M 46.25M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 45.95M 45.99M 46.42M 46.44M 46.50M 46.55M 46.13M 46.17M 46.28M
Normalized Net Operating Profit after Tax (NOPAT)		 15 -6.93 6.31 16 14 23 9.95 16 15 17
Normalized NOPAT Margin		 9.10% -0.83% 3.94% 9.34% 8.41% 2.71% 5.95% 8.98% 9.11% 1.95%
Pre Tax Income Margin		 1.24% -0.57% -16.51% 22.34% 10.13% 11.14% 8.16% 20.55% -82.37% -4.23%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 1.08 -5.12 -0.12 10.25 4.99 0.38 3.94 0.00 -29.78 0.00
NOPAT to Interest Expense		 -0.72 -0.63 -0.08 7.02 3.35 1.14 2.62 0.00 -20.83 0.00
EBIT Less CapEx to Interest Expense		 0.56 -5.62 -0.36 9.37 4.01 0.29 3.08 0.00 -30.65 0.00
NOPAT Less CapEx to Interest Expense		 -1.25 -1.12 -0.33 6.14 2.37 1.05 1.77 0.00 -21.70 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 3.69% -22.36% -51.18% 33.48% 1.39% 0.00% 54.02% -37.86% -17.25%

Frequently Asked Questions About Pacira BioSciences' Financials

When does Pacira BioSciences's fiscal year end?

According to the most recent income statement we have on file, Pacira BioSciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Pacira BioSciences' net income changed over the last 10 years?

Pacira BioSciences' net income appears to be on a downward trend, with a most recent value of -$199.12 million in 2024, rising from -$13.72 million in 2014. The previous period was $83.91 million in 2023. View Pacira BioSciences' forecast to see where analysts expect Pacira BioSciences to go next.

What is Pacira BioSciences's operating income?
Pacira BioSciences's total operating income in 2024 was -$73.37 million, based on the following breakdown:
  • Total Gross Profit: $1.23 billion
  • Total Operating Expenses: $1.59 billion
How has Pacira BioSciences revenue changed over the last 10 years?

Over the last 10 years, Pacira BioSciences' total revenue changed from $197.67 million in 2014 to $1.40 billion in 2024, a change of 609.2%.

How much debt does Pacira BioSciences have?

Pacira BioSciences' total liabilities were at $775.17 million at the end of 2024, a 10.1% increase from 2023, and a 400.3% increase since 2014.

How much cash does Pacira BioSciences have?

In the past 10 years, Pacira BioSciences' cash and equivalents has ranged from $35.94 million in 2016 to $585.58 million in 2021, and is currently $276.77 million as of their latest financial filing in 2024.

How has Pacira BioSciences' book value per share changed over the last 10 years?

Over the last 10 years, Pacira BioSciences' book value per share changed from 4.75 in 2014 to 16.86 in 2024, a change of 255.1%.


Related Companies

This page (NASDAQ:PCRX) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
If you missed your chance with Tesla...
Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...
Brownstone Research | Sponsored
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...
Timothy Sykes | Sponsored
Will May start the next "Great Depression?"
You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...
Behind the Markets | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored